Cover Image
市場調查報告書

類升糖素胜肽2 (GLP2R) :開發中產品分析

Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 386360
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
類升糖素胜肽2 (GLP2R) :開發中產品分析 Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018
出版日期: 2018年02月20日 內容資訊: 英文 46 Pages
簡介

本報告提供以類升糖素胜肽2 (GLP2R) 為目標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括了最新的新聞與發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

類升糖素胜肽2 (GLP2R)的概要

治療藥的開發

  • 開發中的產品 - 各開發階段
  • 開發中的產品 - 各治療範圍
  • 開發中的產品 - 各適應症

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Naia Limited
  • Shire Plc
  • Tasly Pharmaceutical Group Co., Ltd.
  • Zealand Pharma A/S

藥物簡介

暫停中的計劃

主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1297TDB

Summary:

According to the recently published report 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018'; Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.

Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.

The report 'Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H1 2018' outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 2 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Toxicology and Metabolic Disorders which include indications Short Bowel Syndrome, Chemotherapy Effects, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
  • The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
    • Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
    • Adocia SAS
    • Hanmi Pharmaceuticals Co Ltd
    • Naia Ltd
    • Shire Plc
    • Tasly Pharmaceutical Group Co Ltd
    • Zealand Pharma AS
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles
    • FE-203799 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glepaglutide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXG-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-15910 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NB-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teduglutide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teduglutide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPGG-72 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products
  • Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome
      • Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.
      • Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference
      • Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide
      • Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome
      • Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
      • Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
      • Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
      • Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
      • May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome
      • Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016
      • Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome
      • Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX
      • Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan
      • Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by Adocia SAS, H1 2018
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
  • Pipeline by Naia Ltd, H1 2018
  • Pipeline by Shire Plc, H1 2018
  • Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
  • Pipeline by Zealand Pharma AS, H1 2018
  • Dormant Projects, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indications, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top